| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
49,160,000 |
| Market
Cap: |
351.99(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.14 - $13.81 |
|
| Level
I Sector: |
Financials |
| Level
II Sector: |
Financial Services |
| Level
III Sector: |
Diversified Investments |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Co.'s primary product candidate, pemvidutide (proposed INN), is a good laboratory practices-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis. In addition, Co. is developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
300 |
31,500 |
| Total Buy Value |
$0 |
$0 |
$863 |
$138,033 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
1 |
6 |
| Total Shares Sold |
0 |
0 |
0 |
155,302 |
| Total Sell Value |
$0 |
$0 |
$0 |
$2,133,902 |
| Total People Sold |
0 |
0 |
0 |
5 |
| Total Sell Transactions |
0 |
0 |
0 |
9 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Roberts M Scot |
Chief Scientific Officer |
• – – |
2023-01-31 |
4 |
A |
$10.21 |
$14,659 |
D/D |
1,436 |
10,473 |
|
- |
|
| Eisenstadt Richard I |
Chief Financial Officer |
• – – |
2023-01-31 |
4 |
A |
$10.21 |
$11,964 |
D/D |
1,172 |
12,010 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2023-01-31 |
4 |
A |
$10.21 |
$13,230 |
D/D |
1,296 |
13,917 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2023-01-31 |
4 |
A |
$10.21 |
$19,784 |
D/D |
1,938 |
229,713 |
|
- |
|
| Eisenstadt Richard I |
Chief Financial Officer |
• – – |
2022-12-31 |
4 |
D |
$16.45 |
$49,811 |
D/D |
(3,028) |
10,838 |
|
- |
|
| Eisenstadt Richard I |
Chief Financial Officer |
• – – |
2022-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,500 |
13,866 |
|
- |
|
| Pisano Wayne |
Director |
– • – |
2022-12-22 |
4 |
AS |
$15.01 |
$300,268 |
D/D |
(20,000) |
8,498 |
|
-68% |
|
| Pisano Wayne |
Director |
– • – |
2022-12-22 |
4 |
OE |
$2.60 |
$52,000 |
D/D |
20,000 |
28,498 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2022-11-30 |
4 |
D |
$9.95 |
$29,920 |
D/D |
(3,007) |
227,775 |
|
- |
|
| Drutz David |
Director |
– • – |
2022-11-18 |
4 |
OE |
$2.40 |
$334 |
D/D |
139 |
20,151 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2022-10-30 |
4 |
D |
$12.77 |
$38,399 |
D/D |
(3,007) |
230,782 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2022-09-30 |
4 |
D |
$12.77 |
$38,412 |
D/D |
(3,008) |
233,789 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2022-08-31 |
4 |
AS |
$20.02 |
$400,322 |
D/D |
(20,000) |
236,797 |
|
-24% |
|
| Garg Vipin K |
President and CEO |
• • – |
2022-08-30 |
4 |
D |
$18.94 |
$56,953 |
D/D |
(3,007) |
256,797 |
|
- |
|
| Gill John |
Director |
– • – |
2022-08-12 |
4 |
S |
$15.00 |
$40,710 |
D/D |
(2,714) |
2,771 |
|
12% |
|
| Garg Vipin K |
President and CEO |
• • – |
2022-08-12 |
4 |
AS |
$15.06 |
$225,890 |
D/D |
(15,000) |
259,804 |
|
-12% |
|
| Eisenstadt Richard I |
Chief Financial Officer |
• – – |
2022-07-31 |
4 |
A |
$6.86 |
$9,371 |
D/D |
1,366 |
1,366 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2022-07-31 |
4 |
A |
$6.86 |
$5,022 |
D/D |
732 |
9,037 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2022-07-31 |
4 |
A |
$6.86 |
$7,381 |
D/D |
1,076 |
12,621 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2022-07-30 |
4 |
D |
$12.01 |
$36,114 |
D/D |
(3,007) |
274,804 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2022-07-05 |
4 |
AS |
$12.00 |
$122,184 |
D/D |
(10,182) |
8,305 |
|
-12% |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2022-07-05 |
4 |
OE |
$2.95 |
$2,322 |
D/D |
787 |
18,487 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2022-07-01 |
4 |
AS |
$12.00 |
$323,784 |
D/D |
(26,982) |
17,700 |
|
-6% |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2022-07-01 |
4 |
OE |
$2.60 |
$78,190 |
D/D |
26,982 |
44,682 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2022-06-30 |
4 |
D |
$11.70 |
$35,182 |
D/D |
(3,007) |
277,811 |
|
- |
|
417 Records found
|
|
Page 3 of 17 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.11 (1.51%) 
